ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.637,11
0,00%
S&P 500
5.521,52
0,00%
US Dollar vs BRL
5,7628
-0,64%
Bitcoin
83.409,80
2,93%
Brent Oil
70,025
0,14%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Genmab AS (GMAB)

  7. Genmab AS (GMAB) Notícias

GMAB

Genmab AS (GMAB)

Genmab AS
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GMAB
DataHoraFonteTítuloCódigoCompanhia
12/03/202515:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GMABGenmab AS
10/03/202511:13GlobeNewswire Inc.Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38NASDAQ:GMABGenmab AS
20/02/202510:00Business WireEPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
12/02/202518:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GMABGenmab AS
12/02/202515:06Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:GMABGenmab AS
09/12/202414:00Business WireTwo Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)NASDAQ:GMABGenmab AS
08/12/202413:00Business WireInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary AnalysisNASDAQ:GMABGenmab AS
07/12/202421:00Business WireInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
05/11/202414:00Business WireGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual MeetingNASDAQ:GMABGenmab AS
15/09/202409:45Business WireInvestigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialNASDAQ:GMABGenmab AS
19/08/202415:00Business WireTEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
16/08/202410:00Business WireGenmab Announces Changes to its Executive CommitteeNASDAQ:GMABGenmab AS
28/06/202403:00Business WireEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
26/06/202420:08Business WireEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
03/06/202410:00Business WireInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)NASDAQ:GMABGenmab AS
02/06/202418:30Business WirePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular LymphomaNASDAQ:GMABGenmab AS
01/06/202411:00Business WireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)NASDAQ:GMABGenmab AS
23/05/202418:00Business WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:GMABGenmab AS
21/05/202412:10Business WireGenmab Completes Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
14/05/202411:05Business WireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressNASDAQ:GMABGenmab AS
29/04/202419:40Business WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
29/04/202419:40Business WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
03/04/202402:35Business WireGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioNASDAQ:GMABGenmab AS
01/03/202419:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GMABGenmab AS
27/02/202409:45Business WireU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaNASDAQ:GMABGenmab AS
02/02/202408:45Business WireTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
09/01/202409:45Dow Jones NewsPfizer, Genmab Get Speedy FDA Review of Tivdak Full ApprovalNASDAQ:GMABGenmab AS
09/01/202408:45Business WireTIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
09/01/202408:45Business WireTIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical CancerNASDAQ:GMABGenmab AS
09/12/202314:00PR Newswire (US)New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)NASDAQ:GMABGenmab AS
 Apresentando as notícias mais relevantes sobre:NASDAQ:GMAB

Seu Histórico Recente

BOV
EXCO32M
Almacenes Exito
EU
NL0000009645
KLM Airlines
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios